Candel Therapeutics Shares Leap Premarket on FDA Orphan-Drug Designation
By Colin Kellaher
Shares of Candel Therapeutics jumped nearly 30% in premarket trading Thursday after the clinical-stage biopharmaceutical company won a key U.S. Food and Drug Administration designation for the lead product candidate from the adenovirus platform.
Candel said the FDA granted orphan-drug designation to CAN-2409 for the treatment of pancreatic cancer.
The FDA's orphan-drug program gives special status to drugs and biologics for diseases and disorders that affect fewer than 200,000 people in the U.S. and provides for an extended marketing exclusivity period against competition.
Candel recently reported Phase 2 study data showing that CAN-2409, when added to standard of care, more than doubled the median overall survival obtained with standard of care alone in borderline resectable pancreatic cancer.
The Needham, Mass., company last year won FDA fast-track designation for CAN-2409 in pancreatic cancer.
Candel shares, which closed Wednesday at $5.10, were recently up 29% to $6.59 in premarket trading.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
April 11, 2024 09:30 ET (13:30 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s Happening in the Markets This Week
-
Worst-Performing Stock ETFs of the Quarter
-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Consumer Defensives: Despite Angst, Thirsty Investors Have Names to Pursue
-
Industrials: Many Stocks Overvalued After Q3 Outperformance
-
Basic Materials: Despite Index Rise, We See Multiple Long-Term Opportunities
-
What the Election Could Mean for Big Tech Stocks
-
3 Lessons From Recent Stock Market Drama
-
Consumer Cyclicals: Even Amid Moderating Consumer Spending, We See Discounts
-
Healthcare: Valuations Look Fair Overall, With Select Industries Still Undervalued
-
Utilities: Falling Interest Rates, Growth Outlook Boosting Stocks